{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:06:09Z","timestamp":1790611569840,"version":"4.1.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring (TDM) of vancomycin using the ratio of the area under the curve to the minimum inhibitory concentration (AUC\/MIC) is recommended but poses practical challenges. Our community health system implemented AUC-based vancomycin monitoring in 2020 and aimed to assess its impact on clinical and operational outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, quasi-experimental study included 2 arms: trough-based monitoring and AUC-based monitoring. The primary outcome was the time to attainment of the therapeutic target, defined as attainment of an AUC\/MIC ratio of 400 to 600 for the AUC-based monitoring arm or attainment of a trough concentration of 15-20\u2005\u00b5g\/mL for the trough-based monitoring arm. Additional endpoints included treatment failure, vancomycin dose, dose adjustments, and acute kidney injury (AKI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 150 patients (75 per arm) were included, with similar characteristics in both groups: 63% male, average age of 60 years, and common indications of bacteremia, pneumonia, and osteomyelitis. The AUC-based monitoring arm had significantly faster therapeutic target attainment (median, 38\u2005hours vs 62\u2005hours; P &amp;lt; 0.01) and a higher rate of target attainment at first steady-state levels (66.7% vs 22.7%, P &amp;lt; 0.01). No significant differences were observed in vancomycin duration, average daily dose, or AKI. AUC-based vancomycin monitoring resulted in more rapid therapeutic target attainment when compared to trough-based monitoring, resulting in fewer dose adjustments (median, 1 [IQR, 0.0-1.0] vs 1 [IQR, 1.0-2.0]; P &amp;lt; 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The implementation of AUC-based vancomycin monitoring in our community health system led to faster attainment of therapeutic targets, with fewer dose adjustments, suggesting potential for improved clinical efficiency. Further studies are needed to directly assess the impact on patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf289","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:30:39Z","timestamp":1760959839000},"page":"e253-e260","source":"Crossref","is-referenced-by-count":2,"title":["Implementation of vancomycin area under the curve therapeutic drug monitoring: Evaluation of procedural changes at a multihospital community health system"],"prefix":"10.1093","volume":"83","author":[{"given":"Samuel","family":"Morton","sequence":"first","affiliation":[{"name":"Lee Health , Fort Myers, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cubillos","sequence":"additional","affiliation":[{"name":"Lee Health , Fort Myers, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Saunders","sequence":"additional","affiliation":[{"name":"Lee Health , Fort Myers, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-809X","authenticated-orcid":false,"given":"Elisabeth","family":"Chandler","sequence":"additional","affiliation":[{"name":"Lee Health , Fort Myers, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"11","key":"2026032401013207900_zxaf289-B1","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health-Syst Pharm"},{"key":"2026032401013207900_zxaf289-B2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"2026032401013207900_zxaf289-B3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.ijantimicag.2018.08.024","article-title":"Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"52","author":"Mogle","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"2026032401013207900_zxaf289-B4","doi-asserted-by":"publisher","first-page":"1346.e1","DOI":"10.1016\/j.cmi.2020.11.008","article-title":"Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin","volume":"27","author":"Lee","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026032401013207900_zxaf289-B5","doi-asserted-by":"crossref","first-page":"e03313","DOI":"10.1128\/spectrum.03313-22","article-title":"Safety and feasibility assessment of a pharmacy-driven AUC\/MIC vancomycin dosing protocol in a multicenter hospital system","volume":"11","author":"Phillips","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"3","key":"2026032401013207900_zxaf289-B6","doi-asserted-by":"crossref","first-page":"e01602","DOI":"10.1128\/AAC.01602-17","article-title":"Pharmacokinetic\/pharmacodynamic determinants of vancomycin efficacy in Enterococcal bacteremia","volume":"62","author":"Jumah","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"2026032401013207900_zxaf289-B7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"issue":"4","key":"2026032401013207900_zxaf289-B8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2026032401013207900_zxaf289-B9","doi-asserted-by":"crossref","first-page":"e02042","DOI":"10.1128\/AAC.02042-17","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2026032401013207900_zxaf289-B10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.36518\/2689-0216.1502","article-title":"Implementing AUC monitoring in a pharmacist-managed vancomycin dosing protocol: a retrospective cohort study","volume":"4","author":"Robinson","year":"2023","journal-title":"HCA Healthc J Med"},{"issue":"12","key":"2026032401013207900_zxaf289-B11","doi-asserted-by":"crossref","first-page":"e01293","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"61","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026032401013207900_zxaf289-B12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration\u2013time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2026032401013207900_zxaf289-B13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jinf.2008.04.003","article-title":"Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections","volume":"57","author":"Dombrowski","year":"2008","journal-title":"J Infect"},{"key":"2026032401013207900_zxaf289-B14","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf289\/64870228\/zxaf289.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/7\/e253\/64870228\/zxaf289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/7\/e253\/64870228\/zxaf289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:02:28Z","timestamp":1774328548000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/7\/e253\/8299818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":14,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10,22]]},"published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf289","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,1]]},"published":{"date-parts":[[2025,10,22]]}}}